Integrated diagnostic-therapy NuVue combines real-time biopsy needle visualization with targeted therapeutic delivery to soft-tissue cancers, presenting a unified sales proposition to cancer centers seeking streamlined imaging and treatment workflows.

Low-dose advantage Therapeutics claim effectiveness at 1/200 to 1/500 of systemic chemotherapy doses, offering a compelling value proposition around reduced toxicity, improved patient quality of life, and potential for higher patient throughput.

Targeted soft-tissue focus Specialization in liver, pancreatic, and other hard-to-treat soft-tissue cancers positions NuVue to target oncology centers and interventional radiology labs prioritizing precision medicine and site-specific interventions.

Early-stage capital efficiency Current revenue under one million suggests a seed-to-early-commercial phase opportunity; potential sales plays include partnerships with early-adopter hospitals, clinics, and contract research organizations pursuing innovative diagnostics and drug-delivery platforms.

Digital and tech readiness Existing tech stack (Google Fonts API and Apache) indicates a lean, potentially fast-to-deploy digital strategy; sales outreach can emphasize digital marketing, remote demonstrations, and pilot programs with minimal infrastructure requirements.